GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Romany Auclair et al.|New England Journal of Medicine|2022Cited by 383
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L. Smith, Renier J. Brentjens, Sham Mailankody et al.|Cancer Immunology Research|2019Cited by 94